论文部分内容阅读
目的观察依达拉奉治疗急性脑出血的临床效果。方法选择2011年4月—2012年4月收治的急性脑出血患者90例,随机分为对照组和观察组各45例,两组均采用常规的治疗方法,观察组在以上基础上增加依达拉奉30 mg加入100 ml生理盐水静脉滴注,2次/d,2周为1个疗程,共治疗4周。治疗后比较两组疗效,分别于治疗第2、4周末比较两组神经功能损伤评分及日常活动能力评分。计量资料采用t检验,计数资料比较采用χ2检验,P<0.05为差异有统计学意义。结果总有效率观察组93.3%,对照组66.7%,两组比较差异有统计学意义(P<0.05)。神经功能损伤评分观察组治疗第2周末为(20.9±8.4)分,第4周末为(16.4±7.2)分,而对照组相应评分分别为(23.6±7.5)、(21.7±5.9)分;日常活动能力评分观察组治疗第2周末为(66.1±11.4)分,第4周末为(73.9±10.2)分,而对照组相应评分分别为(57.9±10.5)、(67.5±9.3)分(均P<0.05)。结论采用依达拉奉对急性脑出血患者进行治疗能够使患者神经功能的损伤程度有所降低,并能够显著改善临床症状,减轻炎性反应,值得临床推广。
Objective To observe the clinical effect of edaravone in the treatment of acute cerebral hemorrhage. Methods 90 patients with acute cerebral hemorrhage admitted from April 2011 to April 2012 were randomly divided into control group and observation group of 45 cases. Both groups were treated by conventional methods. Lavage 30 mg by adding 100 ml of saline intravenously, 2 times / d, 2 weeks for a course of treatment for a total of 4 weeks. After treatment, the curative effect of the two groups were compared. At the end of the second and the fourth week of treatment, the scores of neurological impairment and daily activities were compared. Measurement data using t test, count data were compared using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate was 93.3% in the observation group and 66.7% in the control group, with significant difference between the two groups (P <0.05). The score of neurological impairment score in the observation group was (20.9 ± 8.4) at the end of the second week, (16.4 ± 7.2) at the fourth week, and (23.6 ± 7.5) and (21.7 ± 5.9) points in the control group respectively. Activity score of the observation group was (66.1 ± 11.4) at the end of the second week and (73.9 ± 10.2) at the end of the fourth week, while the corresponding scores in the control group were (57.9 ± 10.5) and (67.5 ± 9.3) points <0.05). Conclusion The use of edaravone in patients with acute cerebral hemorrhage can reduce the degree of neurological damage and can significantly improve clinical symptoms and reduce inflammatory reactions, is worth clinical promotion.